Food News and Research

RSS

FDA authorizes INDA for recombinant human C1 inhibitor in kidney transplantation

Biotech company Pharming Group NV has announced that the US Food and Drug Administration (FDA) has authorized a clinical study with recombinant human C1 inhibitor (rhC1INH) for the treatment of antibody-mediated rejection (AMR) in kidney transplantation. Dr. Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with rhC1INH under an Investigator IND from the FDA.

3 Sep 2008

Ondansetron helps reduce vomiting, hospital admissions in children with gastroenteritis

University of North Carolina at Chapel Hill researchers have demonstrated that a drug called ondansetron helps reduce vomiting, the need for intravenous fluids and hospital admissions in children with acute gastroenteritis.

3 Sep 2008

Spinifex secures major investment to develop pain drug

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured venture capital investment of A$12 million from GBS Venture Partners Limited, Brandon Capital Partners and Uniseed to fund the development of its pain management drug, EMA401.

2 Sep 2008

Advances in cell therapy bring cure for diabetes step closer

Affecting eight percent of America's population, diabetes can lead to blindness, kidney failure, strokes and heart disease. Thanks to Tel Aviv University researchers, a new cure -- based on advances in cell therapy -- may be within reach.

2 Sep 2008

The impact of soft drink availability in elementary schools on consumption

The consumption of soft drinks is generally considered to be a contributing factor in childhood obesity. Because children spend a substantial amount of time at school, the school food environment plays a central part in shaping eating behaviors.

2 Sep 2008

First patient enrolled in study evaluating S.M.A.R.T. Nitinol self-expandable stent

Cordis Corporation has announced the first patient enrollment in the STROLL trial, which will evaluate the safety and efficacy of the S.M.A.R.T. Nitinol Self-Expandable Stent System in treating patients with obstructive superficial femoral artery (SFA) disease, also known as SFA atherosclerosis.

2 Sep 2008

Mom's depression, baby's sleep linked?

If there's one thing that everyone knows about newborn babies, it's that they don't sleep through the night, and neither do their parents. But in fact, those first six months of life are crucial to developing the regular sleeping and waking patterns, known as circadian rhythms, that a child will need for a healthy future.

2 Sep 2008

Survey reveals confusion of pregnant women

A survey in Britain of mothers and pregnant women has revealed an astonishing level of confusion and perplexity about being pregnant.

2 Sep 2008

Bryostatin extends stroke treatment time to 24 hours, repairs brain tissue

Scientists at the Blanchette Rockefeller Neurosciences Institute (BRNI) have discovered that Bryostatin -- and a related class of drugs discovered at BRNI -- administered 24 hours after stroke can rescue and repair brain tissue. These findings are markedly advanced compared to current stroke treatments that must be administered within three hours and are unable to repair damaged brain tissue.

1 Sep 2008

Advances in the management of diabetes mellitus

The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.

1 Sep 2008

Antiangiogenic and anti-inflammatory drugs: are they safe?

Since Rofecoxib (Vioxx) was withdrawn from the worldwide market based on the safety findings of the Adenomatous Polyp Prevention on Vioxx (APPROVe) study, the uncertainty around the cardiovascular safety of NSAIDs and COX-2 inhibitors remains and leaves practitioners with difficult management decisions for the hundreds of millions of patients worldwide who continue to require pain-relieving therapy to maintain an acceptable quality of life.

1 Sep 2008

British supermarkets guilty of promoting unhealthy foods

British supermarkets have been accused of promoting 'fatty' and unhealthy foods in order to attract customers during the credit squeeze.

1 Sep 2008

Mylan's Alphapharm victorious in Razadyne patent challenge

Mylan Inc. has announced that its subsidiary Alphapharm Pty Limited won a favorable decision in patent litigation against it and Barr Laboratories Inc. relating to Galantamine Tablets, USP, the generic version of Ortho-McNeil's Razadyne Tablets, 4 mg, 8 mg and 12 mg.

31 Aug 2008

Barr receives U.S. approval for generic Razadyne tablets

Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc., received final approval from the U.S. Food & Drug Administration (FDA) to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne (galantamine hydrobromide), 4 mg, 8 mg and 12 mg tablets. Barr intends to launch its generic Razadyne tablets product immediately.

28 Aug 2008

FDA grants IND for Davanat to treat breast cancer patient

Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.

28 Aug 2008

Thiazolidinediones - diabetes drugs carry significant cardiovascular risks

A class of oral drugs used to treat type 2 diabetes may significantly increase the risk of serious cardiovascular events, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members.

28 Aug 2008

Social injustice is killing people on a grand scale reports WHO's Commission

A child born in a Glasgow, Scotland suburb can expect a life 28 years shorter than another living only 13 kilometres away. A girl in Lesotho is likely to live 42 years less than another in Japan. In Sweden, the risk of a woman dying during pregnancy and childbirth is 1 in 17 400; in Afghanistan, the odds are 1 in 8. Biology does not explain any of this. Instead, the differences between - and within - countries result from the social environment where people are born, live, grow, work and age.

28 Aug 2008